Manager × security

HARVEY CAPITAL MANAGEMENT INC REGN holdings history

Who else holds this security? →

REGENERON PHARMACEUTICALS · CUSIP 75886F107 · CIK 1119032

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, HARVEY CAPITAL MANAGEMENT INC reported 4.97K REGN (shares), valued at $3.10M, or 0.64% of its reported non-derivative portfolio. Filed 2026-08-21.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
0.64%
Shares
4.97K
4,975
Reported value
$3.10M
USD

Shares decreased 50.13%; reported value decreased 59.75%, and weight changed -1.12 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20260.64%4,975SEC filing ↗Filed Aug 21, 2026Amended
Q1 20261.76%9,976SEC filing ↗Filed May 11, 2026
Q4 20251.68%10,198SEC filing ↗Filed Feb 17, 2026
Q3 20251.37%11,402SEC filing ↗Filed Oct 31, 2025
Q2 20251.47%11,742SEC filing ↗Filed Aug 14, 2025
Q1 20252.17%13,092SEC filing ↗Filed Apr 30, 2025
Q4 20242.19%13,064SEC filing ↗Filed Jan 29, 2025
Q3 20243.37%12,822SEC filing ↗Filed Oct 29, 2024
Q2 20243.55%12,857SEC filing ↗Filed Jul 22, 2024
Q1 20243.64%12,927SEC filing ↗Filed May 10, 2024
Q4 20233.79%13,004SEC filing ↗Filed Jan 29, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20233.79%13,004$11.42MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Jan 29, 2024
Q1 20243.64%12,927$12.44MShares decreased 0.59%; reported value increased 8.94%, and weight changed -0.15 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 10, 2024
Q2 20243.55%12,857$13.51MShares decreased 0.54%; reported value increased 8.61%, and weight changed -0.09 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Jul 22, 2024
Q3 20243.37%12,822$13.48MShares decreased 0.27%; reported value decreased 0.25%, and weight changed -0.18 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Oct 29, 2024
Q4 20242.19%13,064$9.31MShares increased 1.89%; reported value decreased 30.96%, and weight changed -1.18 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Jan 29, 2025
Q1 20252.17%13,092$8.30MShares increased 0.21%; reported value decreased 10.77%, and weight changed -0.02 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Apr 30, 2025
Q2 20251.47%11,742$6.28MShares decreased 10.31%; reported value decreased 24.36%, and weight changed -0.70 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20251.37%11,402$6.41MShares decreased 2.90%; reported value increased 2.07%, and weight changed -0.10 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Oct 31, 2025
Q4 20251.68%10,198$7.87MShares decreased 10.56%; reported value increased 22.78%, and weight changed +0.31 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20261.76%9,976$7.71MShares decreased 2.18%; reported value decreased 2.08%, and weight changed +0.08 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 11, 2026
Q2 20260.64%4,975$3.10MShares decreased 50.13%; reported value decreased 59.75%, and weight changed -1.12 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 21, 2026
HARVEY CAPITAL MANAGEMENT INC · REGENERON PHARMACEUTICALS

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1119032","quarter":"2026Q2","cusip":"75886F107"}

get_institutional_manager_history
{"cik":"1119032","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.